Needham analyst Michael Matson (NYSE:MATX) maintained a Buy rating on NeoGenomics (NASDAQ:NEO) on Tuesday, setting a price target of $41, which is approximately 29.71% above the present share price of $31.61.
Matson expects NeoGenomics to post earnings per share (EPS) of -$0.17 for the fourth quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in NeoGenomics, with an average price target of $49.
The analysts price targets range from a high of $60 to a low of $41.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $121.34 million and a net profit of -$39.71 million. The company's market cap is $3.89 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 11.0% and a 55.31% success rate.
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.